Structure of 3-CYCLOPENTYLACRYLONITRILE CAS 591769-05-0

3-CYCLOPENTYLACRYLONITRILE CAS 591769-05-0

Identification

CAS Number

591769-05-0

Name

3-CYCLOPENTYLACRYLONITRILE

Synonyms

(2E)-3-Cyclopentyl-2-propenenitrile
(2E)-3-Cyclopentylacrylonitril [German] [ACD/IUPAC Name]
(2E)-3-Cyclopentylacrylonitrile [ACD/IUPAC Name]
(2E)-3-Cyclopentylacrylonitrile [French] [ACD/IUPAC Name]
(2E)-3-Cyclopentylprop-2-enenitrile
1236033-37-6 [RN]
2-Propenenitrile, 3-cyclopentyl-, (2E)- [ACD/Index Name]
3-cyclopentylprop-2-enenitrile
591769-05-0 [RN]
MFCD11857755 [MDL number]
(E)-3-cyclopentylacrylonitrile
(E)-3-cyclopentylprop-2-enenitrile
[591769-05-0] [RN]
2-Propenenitrile, 3-cyclopentyl- [ACD/Index Name]
30459-17-7 [RN]
3-Cyclopentyl-acrylonitrile
95%
CA-5126
DS-8986

SMILES

C1CCC(C1)/C=C/C#N

StdInChI

InChI=1S/C8H11N/c9-7-3-6-8-4-1-2-5-8/h3,6,8H,1-2,4-5H2/b6-3+

StdInChIKey

VMELXYJYSXXORF-ZZXKWVIFSA-N

Molecular Formula

C8H11N

Molecular Weight

121.180

MDL Number

MFCD11857755

Properties

Appearance

Colorless to pale yellow transparent liquid

Safety Data

Symbol

Signal Word

Warning

WGK Germany

3

MSDS Download

Specifications and Other Information of Our 3-CYCLOPENTYLACRYLONITRILE CAS 591769-05-0

Purity

98% min

Shelf Life

2 years

Storage

Known Application

3-CYCLOPENTYLACRYLONITRILE CAS 591769-05-0, as an intermediate for Ruxolitinib, plays a crucial role in the synthesis of Ruxolitinib. Ruxolitinib is a selective Janus kinase (JAK1 and JAK2) inhibitor, primarily used to treat myelofibrosis and polycythemia vera.
Ruxolitinib can inhibit the proliferation and survival of tumor cells, thereby slowing the growth of tumors. Additionally, by inhibiting the JAK-STAT pathway, it can reduce inflammation caused by tumors, alleviating symptoms. The cyclopentyl structure in 3-Cyclopentylacrylonitrile is a crucial part of the Ruxolitinib molecule, essential for the drug’s activity and stability. This unique structure helps Ruxolitinib achieve high selectivity and efficacy in targeting JAK1 and JAK2 kinases, enhancing its therapeutic effect.

General View of Documents

This product is developed by our R&D company Caming Pharmaceutical Limited (http://www.caming.com/).

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).